NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

In regards to

Today we celebrate my Dad passing the 5-year milestone with GBM. We are thankful for the ongoing support from the CCI Edmonton and Northwest Biotherapeutics, and especially for the hours of caregiving my Mom offers every single day! Go Dad! #GBM #Glioblastoma $NWBO pic.twitter.com/PlypOApbpk

— Kristyn Power, CFA (@KristynPower) July 28, 2019

this appears to relate to 1 of the 5 patient stories at 2018 ASCO.

See this tweet:

I'm unbelievably grateful to $NWBO for the treatment options offered to GBM patients. In addition to very encouraging interim results for patient survival, there are also significant quality of life advantages to their treatment. My Dad is the "60 year old man" in the article. https://t.co/KB3UvlxR9L

— Kristyn Power, CFA (@KristynPower) June 7, 2018

Kristyn Power
@KristynPower
Jun 7, 2018
I'm unbelievably grateful to $NWBO for the treatment options offered to GBM patients. In addition to very encouraging interim results for patient survival, there are also significant quality of life advantages to their treatment. My Dad is the "60 year old man" in the article.


https://smithonstocks.com/northwest-biotherapeutics-five-spectacular-patient-outcome-for-patients-treated-with-dcvax-l-as-reported-at-asco-nwbo-0-28-buy/
JUN 5, 2018
includes:

At ASCO, Northwest sponsored a meeting attended by investigators in the phase 3 trial and other oncologists not involved in the trial. During the meeting, five patients gave testimonials on the spectacular outcomes that they had achieved due to treatment with DCVax-L. Four of these patients were treated in compassionate use programs and one was from Linda Liau’s phase 1/2 program at UCLA.

and:

Patient Outcomes for Two Critically Ill GBM Patients who were Surgically Resected Three Times

The case histories of a 60 year old man from Canada and a young mother from the UK were very striking to me. Both had an aggressive, rapidly progressing form of glioblastoma multiforme (GBM). They had relapsed not after one surgical resection, received a second surgical resection and relapsed again and then relapsed after a third. Not many GBM patients have a second surgical resection, because relapse is an indication of an aggressive, probably untreatable cancer. Three resections are extremely rare as it is obvious that the cancer is extremely aggressive and most oncologists would not recommend this. In fact, in both of these cases, the treating physicians recommended against the surgery.

Both patients were told that they had failed all treatment options and had weeks or months to live. Generally, GBM patients who are resected for a second time have six to nine months to live and as I just said, third resections are almost never done. The third resections for these patients were only done because the family insisted. Families of both patients were told that they had no other drug treatment options. However, internet searches turned up information on DCVax-L and they were fortunate to get into the DCVax-L compassionate use program. Both patients were far too sick to be eligible for the DCVax-L phase 3 program.

The 60 year old man had terrible risk factors. Not only had he received three surgical resection, but he was also old and could only be partially resected. Physicians told him he had only weeks to live. He received DCVax-L after the third surgery in October of 2015 and is alive and doing well today-three years later. It was emphasized that he suffered no discernible side effects from DCVax-L treatment.